

Monitoring of quality indicators for antibiotic use in Belgian hospitals Are we improving?

Ann Versporten, for BAPCOC, the Belgian antibiotic therapy policy groups and the Global-PPS network


Contact:

Ann.Versporten@health.fgov.be





1,5-hour Oral Session, July 9 (10:45-12:15) 2021









Disclosures

"bioMérieux is the sole private sponsor of the Global Point
Prevalence Survey. The Global-PPS is also funded by a
personal Methusalem grant to Herman Goossens of the
Flemish government. The funder has no role in study design,
data collection, data analysis, data interpretation, or writing
the report. Data are strictly confidential and stored
anonymously at the coordinating centre of the University of
Antwerp."



Point Prevalence Surveys in Belgium - Background : the 2014-2019 policy paper -

- 2014-2019 policy paper of the Belgian Antibiotic Policy Coordination Committee (BAPCOC) defined hospital-based antibiotic quality indicators and target values. (https://consultativebodies.health.belgium.be/en/Node/483)
- Main objective of policy paper:
 - Consolidate the functioning of the antibiotic policy groups by law institutionalized in each Belgian hospital (ABTBG/GGA)
 - Improve the quality of antibiotic use by means of quality indicators

QUALITY INDICATORS HOSPITAL	TARGET	Measured by PPS	
Choice of therapeutic antibiotics following local instructions		Guideline compliance therapeutic antibiotics	
Indication statement of antibiotic therapy in the medical record	In at least 90% of	Reason of antibiotic therapy written in notes	
Choice of surgical antibiotic prophylaxis following local instructions	the cases by 2019	Guideline compliance antibiotics for SP	
Duration of surgical antibiotic prophylaxis following local instructions		Proxy: SP > 1 day (also done through different audit on SP)	



Point Prevalence Surveys in Belgium - Aim and Methods -

Aim of current study: Assess whether 90% compliance of the stewardship goals were achieved by 2019.

Methods:

- Global point prevalence surveys (<u>www.Global-PPS.com</u>) were conducted in 2015, 2017 (ECDC-PPS included) and 2019.
- All patients present in the wards on day of the PPS at 8 a.m. were included.
- Detailed data collected for patients on antimicrobials included AMU and HAI patterns and antibiotic quality indicators.
- Current analyses: patients admitted on neonatal wards were excluded.
- Prevalence rates on AMU and HAI were weighted by department type.



Degree of participation, AMU and HAI prevalence

	2015 ⁽¹⁾	2017 (including ECDC-PPS 2)	2019 ⁽⁴⁾
N included hospital sites	100	110	76
N admitted patients	26,315	28,023	20,370
N patients with at least one AM prescription on the day of PPS	7212	7565	5452
Crude AMU prevalence (%; 95%CI) Crude HAI prevalence (%; 95%CI)	26.7 (25.1-28.3) 7.8 (7.1-8.5)	26.9 (25.3-28.5) 7.3 (6.7-7.9)	27.9 (26.1-29.7) 7.1 (6.4-7.8)

References:

hospitals.http://www.nsih.be/download/GM/Sciensano_National%20report %20antimicrobial%20consumption%202010-

2019_version%2020210329.pdf



¹ Versporten A. et al. Lancet Glob Health. 2018;6(6):e619–29.


².http://www.nsih.be/download/ECDC%20PPS/nationalreport_ECDCPPS2 017_Belgium_20181119.pdf


³ Vandael E. et al. Antimicrob Resist Infect Control. 2020;9:13.

⁴·Antimicrobial Consumption in Belgium. 10-year evolution (2010-2019) in the community, nursing homes and



Antibiotic quality indicators






CAI & HAI = Community-acquired and Healthcare-associated infections = therapeutic use Selection on antibacterials for systemic use (ACT code J01)


Neonatal wards are excluded from these analyses

2017 ECDC-PPS data not available for guideline compliance and excluded for reason in notes



Antibiotic quality indicators







CAI & HAI = Community-acquired and Healthcare-associated infections = therapeutic use Selection on antibacterials for systemic use (ACT code J01)

Neonatal wards are excluded from these analyses
2017 ECDC-PPS data not available for stop/review date



Antibiotic quality indicators





CAI & HAI = Community-acquired and Healthcare-associated infections = therapeutic use Selection on antibacterials for systemic use (ACT code J01)

Neonatal wards are excluded from these analyses

2017 ECDC-PPS data not available for targeted prescribing

Bron = Bronchitis; Pneu = Pneumonia; SST = Skin & soft tissue infections

Frenette et al.The 2017 global point prevalence survey of antimicrobial consumption and resistance in Canadian hospitals, *Antimicrob. Resist. Infect. Control*. 2020; 9: 104, Canadian (14 hospitals). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7353732/

Contact:

Global-PPS@uantwerpen.be

Findings

- Antimicron and Consumption and
- Satisfactory N hospital sites with motivated teams over time.
- AMU and HAI prevalence remained stable over time.
- All antibiotic quality indicators showed a steady slight improvement over time, but few reached the target compliance of 90% in 2019.
- Less than half of therapeutic antibiotic prescriptions had a "stop/review date documented in the medical record".
- Slight increase of targeted therapeutic antibiotic prescribing.

The way forward!



- Further investigation needed > examine what kind of stewardship interventions were put in place at hospital level which have led to the improvements observed
- Install a system to enhance the documentation of a stop/review date; preferably integrated in the hospital's electronic systems to enable information exchange with the hospital pharmacy
- The antibiotic policy groups at hospital level have the continued task of supervising and sensitizing physicians. Hospitals will be financially supported through the HOST project.

https://organesdeconcertation.sante.belgique.be/fr/projet-pilote-hospital-outbreak-support-teams-host